COSTS OF CONTINUOUS SUBCUTANEOUS INSULIN INFUSION AND MULTIPLE-DOSE INSULIN THERAPIES FOR TYPE 1 DIABETES MELLITUS: A REVIEW OF HEALTH ECONOMICS STUDIES

Resumo

Multiple Doses of Insulin and Continuous Subcutaneous Insulin Infusion are the most used technologies for the treatment of Type 1 Diabetes Mellitus due to the favorable impact in glycemic control. The objective was to evaluate the two forms of Type 1 Diabetes Mellitus treatment through cost-effectiveness, cost-benefit, and cost-utility. A bibliographic search was carried out, including nine databases: Institute of Electrical and Electronic Engineers, International Society for Pharmacoeconomics and Outcomes Research, Scientific Eletronic Library, Medline, Ovid, Springer, Compendex, Scopus and Inspec. The search was limited to articles in English, Portuguese, and Spanish published during the last twenty-five years, and a total of 42 studies were included in the research. The costs associated with the use of the Continuous Subcutaneous Insulin Infusion are higher, however, associations were found between its use and the improvement in the HbA1c levels and the year of life adjusted to quality, such as reducing the chronic fear of severe hypoglycemia, greater flexibility in lifestyle and participation in social and physical activities, in addition reducing glycemic oscillations and episodes of hypoglycemia. Therefore, the clinical benefits of Continuous Subcutaneous Insulin Infusion are evident, and it is important to mention that studies show that the higher costs that treatment may be partially mitigated by a reduction of the expenses in treating T1DM-related complications, and the additional costs can be recovered within few years.

DOI: http://dx.doi.org/10.16891/2317-434X.v9.e2.a2021.pp1034-1046